Stockscreener 앱 받기
12.89
1.53%
-0.20
시간 외 거래:
12.88
-0.010
-0.08%
전일 마감가:
$13.09
열려 있는:
$13.14
하루 거래량:
383.20K
Relative Volume:
0.19
시가총액:
$735.82M
수익:
-
순이익/손실:
$-72.89M
주가수익비율:
-5.3264
EPS:
-2.42
순현금흐름:
$-68.47M
1주 성능:
-0.46%
1개월 성능:
+2.30%
6개월 성능:
+124.96%
1년 성능:
+43.70%
1일 변동 폭
$12.85
$13.14
1주일 범위
$12.85
$13.14
52주 변동 폭
$3.555
$13.29
Astria Therapeutics Inc Stock (ATXS) Company Profile
명칭
Astria Therapeutics Inc
전화
617-349-1971
주소
22 BOSTON WHARF ROAD, BOSTON
ATXS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
12.89 | 747.24M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-09-17 | 재확인 | H.C. Wainwright | Buy |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-01-31 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-29 | 개시 | TD Cowen | Buy |
| 2023-03-28 | 개시 | Evercore ISI | Outperform |
모두보기
Astria Therapeutics Inc 주식(ATXS)의 최신 뉴스
Patterns Watch: Is Astria Therapeutics Inc stock gaining market shareMarket Performance Summary & Capital Efficiency Focused Strategies - moha.gov.vn
Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of “Hold” by Brokerages - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Astria Therapeutics’ STAR-0310 Study: A Promising Step Forward - MSN
Astria Therapeutics Advances Phase 3 Trial for Hereditary Angioedema Treatment - MSN
(ATXS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Astria Therapeutics IncComplaints filed against Astria in New York Supreme CourtSEC filing - marketscreener.com
Astria Faces Shareholder Lawsuits Over Planned BioCryst Merger - TipRanks
Astria Therapeutics Merger with BioCryst Pharmaceuticals - TradingView — Track All Markets
Halper Sadeh LLC Encourages ATXS, GDOT, UBFO Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-ATXS, MBCN, FMNB, and SEMR - The Malaysian Reserve
Why Astria Therapeutics Inc. stock could outperform in 2025Weekly Market Outlook & High Win Rate Trade Alerts - Улправда
Why Astria Therapeutics Inc. stock appeals to dividend seekersJuly 2025 Reactions & Accurate Entry/Exit Alerts - DonanımHaber
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ATXS, MBCN, FMNB, and SEMR - Sahm
Astria Therapeutics Earnings Notes - Trefis
Astria Therapeutics (ATXS) price target decreased by 17.94% to 21.62 - MSN
Technical Reactions to ATXS Trends in Macro Strategies - Stock Traders Daily
FDA approves BioCryst's oral pellet version of swelling disorder drug for children - Reuters
BioCryst Pharmaceuticals announces board chair transition following retirement notice By Investing.com - Investing.com UK
BioCryst Pharmaceuticals announces board chair transition following retirement notice - Investing.com
Astria Therapeutics, Inc. $ATXS Shares Acquired by JPMorgan Chase & Co. - MarketBeat
Panagora Asset Management Inc. Purchases New Holdings in Astria Therapeutics, Inc. $ATXS - MarketBeat
Affinity Asset Advisors LLC Purchases Shares of 300,000 Astria Therapeutics, Inc. $ATXS - MarketBeat
Will Astria Therapeutics Inc. stock gain from government policies2025 Market Overview & Verified Swing Trading Watchlists - Newser
Astria Therapeutics (NASDAQ:ATXS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Hold" from Analysts - MarketBeat
BioCryst’s Ongoing Boost: Buy or Watch? - StocksToTrade
Astria Therapeutics (NASDAQ:ATXS) Sets New 1-Year HighWhat's Next? - MarketBeat
Astria Therapeutics (ATXS) Acquisition Moves Forward with Antitr - GuruFocus
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition - The Manila Times
BioCryst Pharmaceuticals Announces Early Termination of HSR Waiting Period for Astria Therapeutics Acquisition - Quiver Quantitative
BioCryst receives antitrust clearance for Astria acquisition - Investing.com
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-TCBX, RNA, ATXS, and FSUN - The Malaysian Reserve
Trading the Move, Not the Narrative: (ATXS) Edition - news.stocktradersdaily.com
Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights - Sahm
Astria Therapeutics: Updating Target Price, BioCryst Deal Expected To Go Through, Hold - Seeking Alpha
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-SPNS, PCH, ATXS, and RYN - The Malaysian Reserve
Halper Sadeh LLC Encourages ATXS, PCH, RYN Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
(ATXS) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Will Astria Therapeutics Inc. stock split again soonJuly 2025 Summary & High Yield Equity Trading Tips - newser.com
How Astria Therapeutics Inc. stock performs in interest rate cycles2025 Retail Activity & Fast Exit Strategy with Risk Control - newser.com
Will Astria Therapeutics Inc. stock deliver consistent dividendsJuly 2025 Review & Weekly High Potential Alerts - newser.com
Can Astria Therapeutics Inc. stock deliver surprise earnings beatWeekly Stock Analysis & Fast Momentum Stock Entry Tips - newser.com
Can Astria Therapeutics Inc. stock outperform in 2025 bull marketPortfolio Return Summary & Detailed Earnings Play Alerts - newser.com
Combining price and volume data for Astria Therapeutics Inc.2025 Support & Resistance & Long-Term Safe Return Strategies - newser.com
Astria Therapeutics Inc (ATXS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
자본화:
|
볼륨(24시간):